MannKind (MNKD) Competitors $5.76 +0.11 (+1.86%) Closing price 03:59 PM EasternExtended Trading$5.81 +0.04 (+0.78%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MNKD vs. ALKS, IONS, FOLD, LGND, BCRX, DVAX, GERN, CLDX, MYGN, and NVAXShould you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), Geron (GERN), Celldex Therapeutics (CLDX), Myriad Genetics (MYGN), and Novavax (NVAX). These companies are all part of the "biotechnology" industry. MannKind vs. Alkermes Ionis Pharmaceuticals Amicus Therapeutics Ligand Pharmaceuticals BioCryst Pharmaceuticals Dynavax Technologies Geron Celldex Therapeutics Myriad Genetics Novavax Alkermes (NASDAQ:ALKS) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Does the MarketBeat Community favor ALKS or MNKD? Alkermes received 118 more outperform votes than MannKind when rated by MarketBeat users. Likewise, 70.52% of users gave Alkermes an outperform vote while only 60.17% of users gave MannKind an outperform vote. CompanyUnderperformOutperformAlkermesOutperform Votes70170.52% Underperform Votes29329.48% MannKindOutperform Votes58360.17% Underperform Votes38639.83% Do insiders & institutionals believe in ALKS or MNKD? 95.2% of Alkermes shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 4.9% of Alkermes shares are held by company insiders. Comparatively, 3.0% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ALKS or MNKD more profitable? Alkermes has a net margin of 23.57% compared to MannKind's net margin of 8.07%. Alkermes' return on equity of 30.80% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.57% 30.80% 19.09% MannKind 8.07%-17.74%8.68% Which has higher valuation & earnings, ALKS or MNKD? Alkermes has higher revenue and earnings than MannKind. Alkermes is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.69$367.07M$2.1716.28MannKind$198.96M7.99-$11.94M$0.0782.36 Which has more risk & volatility, ALKS or MNKD? Alkermes has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Does the media prefer ALKS or MNKD? In the previous week, Alkermes had 15 more articles in the media than MannKind. MarketBeat recorded 19 mentions for Alkermes and 4 mentions for MannKind. Alkermes' average media sentiment score of 0.48 beat MannKind's score of 0.42 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 8 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ALKS or MNKD? Alkermes currently has a consensus price target of $38.36, indicating a potential upside of 8.60%. MannKind has a consensus price target of $9.21, indicating a potential upside of 59.83%. Given MannKind's stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82MannKind 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryAlkermes beats MannKind on 13 of the 19 factors compared between the two stocks. Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNKD vs. The Competition Export to ExcelMetricMannKindPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.59B$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio82.366.1326.4618.82Price / Sales7.99313.78457.6880.73Price / CashN/A67.8344.0437.47Price / Book-6.346.747.634.64Net Income-$11.94M$138.11M$3.18B$245.69M7 Day Performance6.37%-2.02%-1.82%-2.63%1 Month Performance-4.55%-1.54%0.22%-2.37%1 Year Performance60.14%-3.14%17.49%13.65% MannKind Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNKDMannKind2.7679 of 5 stars$5.77+1.9%$9.21+59.8%+57.2%$1.59B$198.96M82.36400ALKSAlkermes3.6702 of 5 stars$35.89-0.3%$37.25+3.8%+16.8%$5.81B$1.66B18.412,100IONSIonis Pharmaceuticals4.4237 of 5 stars$31.04+2.3%$60.65+95.4%-26.3%$4.90B$788M-12.72800Earnings ReportAnalyst ForecastNews CoverageFOLDAmicus Therapeutics4.1863 of 5 stars$9.77+1.3%$16.88+72.7%-33.8%$2.92B$399.36M-28.74480Analyst DowngradeNews CoverageLGNDLigand Pharmaceuticals4.1494 of 5 stars$120.00+5.3%$147.00+22.5%+68.6%$2.27B$131.31M47.8180Positive NewsBCRXBioCryst Pharmaceuticals3.9384 of 5 stars$9.05+2.6%$15.50+71.3%+61.3%$1.87B$331.41M-14.84530High Trading VolumeDVAXDynavax Technologies4.2713 of 5 stars$12.82+1.0%$21.50+67.7%+8.6%$1.69B$232.28M98.62350Earnings ReportAnalyst ForecastNews CoverageGap UpGERNGeron3.1622 of 5 stars$2.56-8.2%$7.25+183.2%+34.1%$1.55B$240,000.00-8.0070Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeCLDXCelldex Therapeutics1.3405 of 5 stars$22.70-1.6%$60.22+165.3%-41.3%$1.51B$6.88M-8.83150MYGNMyriad Genetics3.8504 of 5 stars$14.56-0.6%$22.54+54.8%-36.3%$1.33B$753.20M-11.202,700Analyst DowngradeNVAXNovavax4.0931 of 5 stars$8.19+0.1%$17.83+117.7%+91.8%$1.31B$983.71M-3.621,543Analyst RevisionNews Coverage Related Companies and Tools Related Companies Alkermes Alternatives Ionis Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Ligand Pharmaceuticals Alternatives BioCryst Pharmaceuticals Alternatives Dynavax Technologies Alternatives Geron Alternatives Celldex Therapeutics Alternatives Myriad Genetics Alternatives Novavax Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MNKD) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
